Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation

Cellular and Molecular Immunology

Volumn 13, Issue 3, 2016, Pages 379-390

  Wu, Yanwei ^a   He, Shijun ^a   Bai, Bingxin ^a   Zhang, Luyao ^a   Xue, Lu ^a   Lin, Zemin ^a   Yang, Xiaoqian ^a   Zhu, Fenghua ^a   He, Peilan ^a   Tang, Wei ^a   Zuo, Jianping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; ARTEMISININ DERIVATIVE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 21; INTERLEUKIN 6; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PREDNISOLONE; SM 934; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; ARTEMISININ; AUTOANTIBODY; BETA-AMINOARTEETHER MALEATE; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CELL COMPARTMENTALIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREGULATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR DOWN REGULATION; SPLEEN CELL; AGONISTS; ANIMAL; BLOOD; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; HUMORAL IMMUNITY; IMMUNOLOGY; LUPUS NEPHRITIS; LYMPHADENOPATHY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SPLEEN; SPLENOMEGALY; SURVIVAL ANALYSIS;

ANIMALS; ARTEMISININS; AUTOANTIBODIES; CELL COMPARTMENTATION; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNITY, HUMORAL; LUPUS NEPHRITIS; LYMPHADENOPATHY; LYMPHOCYTE ACTIVATION; MICE, INBRED MRL LPR; MYELOID DIFFERENTIATION FACTOR 88; PLASMA CELLS; SIGNAL TRANSDUCTION; SPLEEN; SPLENOMEGALY; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTORS;

EID: 84966376846     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.13     Document Type: Article

References (47)

1. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269-390.
2. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002; 17: 51-62.
3. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 Represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000; 13: 199-212.
4. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
5. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000; 53: 424-432.
6. Muro Y. Antinuclear antibodies. Autoimmunity 2005; 38: 3-9.
7. Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol 2012; 10: 103-106.
8. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-607.
9. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005; 202: 1171-1177.
10. Teichmann LL, Schenten D, Medzhitov R, Kashgarian M, Shlomchik MJ. Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity 2013; 38: 528-540.
11. Robak E, Sysa-Jedrzejowska A, Stepien H, Robak T. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur Cytokine Network 1997; 8: 281-286.
12. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer- Varela J et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839-844.
13. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi- Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R. Fc reduces disease progression. J Immunol 2007; 178: 3822-3830.
14. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 2004; 173: 5361-5371.
15. Deng XM, Yan SX, Wei W. IL-21 acts as a promising therapeutic target in systemic lupus erythematosus by regulating plasma cell differentiation. Cell Mol Immunol 2015; 21: 31-39.
16. Rankin AL, Guay H, Herber D, Bertino SA, Duzanski TA, Carrier Y et al. IL-21 receptor is required for the systemic accumulation of activated Band T lymphocytes in MRL/MpJ-Faslpr/lpr/J mice. J Immunol 2012; 188: 1656-1667.
17. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007; 27: 461-466.
18. Lu L. [Study on effect of Cordyceps sinensis and artemisinin in preventing recurrence of lupus nephritis]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2002; 22: 169-171. Chinese.
19. Jin O, Zhang H, Gu Z, Zhao S, Xu T, Zhou K et al. A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus. Cell Mol Immunol 2009; 6: 461-467.
20. Wu X, Zhang W, Shi X, An P, Sun W, Wang Z. Therapeutic effect of artemisinin on lupus nephritis mice and its mechanisms. Acta Biochim Biophys Sin 2010; 42: 916-923.
21. Hou LF, He SJ, Wang JX, Yang Y, Zhu FH, Zhou Y et al. SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo. Int Immunopharmacol 2009; 9: 1509-1517.
22. Hou LF, He SJ, Li X, Yang Y, He PL, Zhou Y et al. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum 2011; 63: 2445-2455.
23. Hou LF, He SJ, Li X, Wan CP, Yang Y, Zhang XH et al. SM934 treated lupus-prone NZB3NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development. PLoS One 2012; 7: e32424.
24. Monahan E, Yamazaki K. An improved urine collection technique for laboratory mice: the bladder massage method. Lab Animal (USA) 1993; 38-39.
25. Yang LY, Chen A, Kuo YC, Lin CY. Efficacy of a pure compound H1-A extracted from Cordyceps sinensis on autoimmune disease of MRL lpr/lpr mice. J Lab Clin Med 1999; 134: 492-500.
26. Tao X, Fan F, Hoffmann V, Longo NS, Lipsky PE. Therapeutic impact of the ethyl acetate extract of Tripterygium wilfordii Hook F on nephritis in NZB/W F1 mice. Arthritis Res Ther 2006; 8: R24.
27. Tao X, Fan F, Hoffmann V, Gao CY, Longo NS, Zerfas P et al. Effective therapy for nephritis in (NZB3NZW) F1 mice with triptolide and tripdiolide, the principal active components of the Chinese herbal remedy Tripterygium wilfordii Hook F. Arthritis Rheum 2008; 58: 1774-1783.
28. Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008; 58: 1433-1444.
29. Tan X, Fan F, Hoffman V, Longo NS, Lipsky PE. Therapeutic impact of the ethyl acetate extract of Tripterygium wilfordii Hook F on nephritis in NZB/W F1 mice. FASEB J 2006; 20: A1147.
30. He SJ, Lin ZM, Wu YW, Bai BX, Yang XQ, He PL et al. Therapeutic effects of DZ2002, a reversible SAHH inhibitor, on lupus-prone NZB3NZW F1 mice via interference with TLR-mediated APC response. Acta Pharmacol Sin 2014; 35: 219-229.
31. Avalos AM, Busconi L, Marshak-Rothstein A. Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity 2010; 43: 76-83.
32. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell Richard A, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006; 25: 417-428.
33. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 823-835.
34. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 5970-5979.
35. Sadanaga A, Nakashima H, Akahoshi M, Masutani K, Miyake K, Igawa T et al. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum 2007; 56: 1618-1628.
36. Xu L, Chen X, Tu Y. Efect of hydroartemisinin on lupus BXSB mice. Chin J Dermatovenerol Integr Tradit West Med 2002; 1: 19-20.
37. Hou L, Block KE, Huang H. Artesunate abolishes germinal center B cells and inhibits autoimmune arthritis. PLoS One 2014; 9: e104762.
38. Ditzel HJ. The K/BxN mouse: a model of human inflammatory arthritis. Trends Mol Med 2004; 10: 40-45.
39. William J, Euler C, Christensen S, Shlomchik MJ. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 2002; 297: 2066-2070.
40. Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A et al. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett 2003; 552: 141-144.
41. Li WD, Dong YJ, Tu YY, Lin ZB. Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation. Int Immunopharmacol 2006; 6: 1243-1250.
42. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center b cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001; 167: 2361-2369.
43. Shlomchik MJ, Euler CW, Christensen SC, William J. Activation of rheumatoid factor (RF) B cells and somatic hypermutation outside of germinal centers in autoimmune-prone MRL/lpr mice. Ann NY Acad Sci 2003; 987: 38-50.
44. William J, Euler C, Shlomchik MJ. Short-lived plasmablasts dominate the early spontaneous rheumatoid factor response: differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center. J Immunol 2005; 174: 6879-6887.
45. Moore KW, de Waal Malefyt R, Coffman RL, OGarra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
46. Gröndal G, Gunnarsson I, Rönnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1999; 18: 565-570.
47. Park Y, Lee S, Kim D, Lee J, Lee C, Song C. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1997; 16: 283-288.